Terazosin hydrochloride hydrate

盐酸特拉唑嗪水合物

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameTerazosin hydrochloride hydrate
Drug Alias NameTerasin特拉哇嗦盐酸特拉唑秦水合物tidazosinterazosinum +[25] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdrenergic receptors antagonists
TargetsAdrenergic receptors
Therapy Area/IndicationsUreteral Stent-Related SymptomEssential HypertensionHypertension +[9] 
Global Approved IndicationsEssential HypertensionHypertensionUrination Disorders +[5] 
Approved Indications in ChinaHypertensionProstatic Hyperplasia
Original Approved Country/TerritoryUnited States
Original Approved Date1987/08/07
Country/TerritoryUnited StatesMainland ChinaMalaysia +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAbbott Laboratories
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of IowaPenang Adventist HospitalHainan Green Island Pharmacentical +[4] 
Inactive CompaniesAbbott LaboratoriesCapital Medical University
Active IndicationsUreteral Stent-Related SymptomEssential HypertensionHypertension +[8] 
Inactive IndicationsCarotid Stenosis

Other Information

ATC CodeG04CA03
Related LinksWikipediaDrugBankKEGG